Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 7/20 | 0.77 |
| ▸ | CA1 | P00915 | 7/20 | 0.77 |
| ▸ | CA2 | P00918 | 7/20 | 0.77 |
| ▸ | CA9 | Q16790 | 7/20 | 0.77 |
| ▸ | CA6 | P23280 | 6/20 | 0.77 |
| ▸ | CA7 | P43166 | 6/20 | 0.77 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.77 |
| ▸ | CA5B | Q9Y2D0 | 6/20 | 0.77 |
| ▸ | CA5A | P35218 | 5/20 | 0.77 |
| ▸ | CISD1 | Q9NZ45 | 3/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.77 |
| ▸ | HTR1A | P08908 | 1/20 | 0.77 |
| ▸ | CA4 | P22748 | 1/20 | 0.77 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.77 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.77 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.77 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.77 |
| ▸ | APP | P05067 | 9/20 | 0.62 |
| ▸ | CA3 | P07451 | 5/20 | 0.61 |
| ▸ | CA13 | Q8N1Q1 | 5/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29436031 | 0.91 | CA12 (0.76) | CA12CA1CA2CA9CA6 | |
| SCHEMBL10837475 | 0.90 | CA12 (0.82) | CA12CA1CA2CA9CA6 | |
| SCHEMBL14369223 | 0.90 | CA12 (0.74) | CA12CA1CA2CA9CA6 | |
| SCHEMBL2880956 | 0.89 | CA12 (0.83) | CA12CA1CA2CA9CA6 | |
| SCHEMBL29436046 | 0.89 | CA1 (0.79) | CA12CA1CA2CA9CA6 | |
| SCHEMBL229073 | 0.88 | CA12 (0.85) | CA12CA1CA2CA9CA6 | |
| Furosemide SCHEMBL428921 | 0.87 | CISD1 (1.00) | CA12CA1CA2CA9CA6 | |
| Furosemide SCHEMBL29406913 | 0.87 | CISD1 (1.00) | CA12CA1CA2CA9CA6 | |
| Furosemide SCHEMBL9811 | 0.87 | CISD1 (1.00) | CA12CA1CA2CA9CA6 | |
| Furosemide SCHEMBL6751172 | 0.86 | CISD1 (0.98) | CA12CA1CA2CA9CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1668008-A4 | NITROSATED AD NITROSYLATED DIURETIC COMPOUDS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2009-02-25 | — | — | EP | claimed |
| EP-1668008-A2 | NITROSATED AD NITROSYLATED DIURETIC COMPOUDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2006-06-14 | — | — | EP | claimed |
| WO-2005023183-A2 | NITROSATED AD NITROSYLATED DIURETIC COMPOUDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2005-03-17 | — | — | WO | claimed |
| US-20050059655-A1 | Nitrosated and nitrosylated diuretic compounds, compositions and methods of use | NITROMED, INC. (US) | 2005-03-17 | — | — | US | claimed |
| EP-1668008-A4 | NITROSATED AD NITROSYLATED DIURETIC COMPOUDS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2009-02-25 | — | — | EP | disclosed |
| US-7282519-B2 | Nitrosated and nitrosylated diuretic compounds, compositions and methods of use | NITROMED, INC. (US) | 2007-10-16 | — | — | US | disclosed |
| EP-1668008-A2 | NITROSATED AD NITROSYLATED DIURETIC COMPOUDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005023183-A2 | NITROSATED AD NITROSYLATED DIURETIC COMPOUDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| US-20050059655-A1 | Nitrosated and nitrosylated diuretic compounds, compositions and methods of use | NITROMED, INC. (US) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059655-A1 | Nitrosated and nitrosylated diuretic compounds, compositions and methods of use | REN, NOS1, NOS3 | CA12 1897/4885CA1 1129/4885CA2 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.